FDA to accelerate Exjade review

The FDA has agreed to give Novartis a priority review for Exjade, an experimental treatment that removes excess iron in the blood. And analysts say the move may allow the drug giant to start marketing the drug by the end of this year. Potential sales estimates range from $200 million to $700 million a year.

- read this story from MarketWatch for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.